IES85567Y1 - Manufacture of beta blockers - Google Patents

Abstract

ABSTRACT Bisoprolol base is prepared by convening bisoprolol fumarate to bisoprolol base and isolzning the bisoprolol base.

Description

Introduction This invention relates to the manufacture of Bisoprolol fiimarate and intermediates used in the process.

The process described in DOS 2 645 710, describes a process wherein 2- (isopropoxy)ethoxymethy1-phenol is reacted with epichlorhydrin and the [5-amino alcohol moiety is formed by the addition of iso-propylamine. This synthetic route suffers from several disadvantages including the handling of epichlorohydrin which is a known carcinogen and can undergo violent reactions or exothermic polymerisation on contact with amines or alkoxides. In addition, the reaction between the epoxy intermediate and isopropylamine has the potential to undergoes side reactions leading to the formation of the known impurity F (as described in the European Pharmacopeia 6.1).

DOS320S457 describes a process wherein the 2-(isopropoxy)ethoxymethyl substituent is introduced in two stages. Initially the aromatic ring of 3-isopropy1- -phenoxymethyl-oxazolidinone is chloromethylated using HC1 and paraformaldehyde followed by a Williamson ether synthesis employing metallic sodium. The resultant oxazolidine ring is cleaved by alkaline hydrolysis.

Bisoprolul Fumxrate Imp G This synthetic route suffers from several disadvantages including the handling of metallic sodium which can undergo violent reactions on contact with water or alcohols. In addition the chloromethylation of 3-isopropylphenoxymethyl- oxazolidinone with parafonnaldehyde in the presence of HC1 undergoes side reactions leading to the formation of the known impurities C and G. This process generates material of inferior quality as exemplified by a limit for impurity G of .5% (as described in the European Pharmacopeia 6.1).

Statements of Invention According to the invention there is provided a process for preparing bisoprolol comprising the steps of:- reacting oxazolidinone sulphonate with 4-hydroxybenzylaldehyde to form oxazolidinone benzaldehyde; forming oxazolidone benzylalcohol from oxazolidone benzaldehyde; and subsequently reacting oxazolidinone benzylalcohol with isopropyl oxitol to form bisoprolol base.

In one embodiment the oxazolidone sulphonate is formed by reacting isopropylaminopropanediol with dimethylcarbonate and reacting the intermediate product thus formed with benzenesulphonylchloride.

In one case oxazolidinone sulphonate is not isolated prior to reaction with 4- hydroxybenzaldehyde.

In one embodiment methylisobutylketone is added to the intermediate product prior to the addition of benzenesulphonylchloride. In this case the reaction between the intermediate and benzenesuphonyl chloride may be performed under phase transfer conditions utilising water soluble bases such as sodium hydroxide.

Alternatively, the reaction between the intermediate and benzenesulphonyl chloride is performed in an organic solvent such as methylisobutylketone utilising bases soluble in organic solvents such as triethylamine.

The process may comprise the step of purifying bisoprolol base. The bisoprolol base may be purified by distillation. The bisoprolol base may be purified by crystallisation.

The process may comprise the step of forming bisoprolol fumarate by reacting bisoprolol base with fumaric acid.

In one embodiment the process comprises converting bisoprolol fumarate to bisoprolol base.

The invention also provides bisoprolol prepared by a process as described herein.

The invention further provides bisoprolol fumarate prepared by a process as described herein.

The invention also provides a process for preparing oxazolidinone benzaldehyde by reacting oxazolidinone sulphonate with 4-hydroxybenzylaldehyde.

The process for preparing oxazolidone benzylalcohol may comprise converting oxazolidone benzaldehyde to oxazolidone benzylalcohol.

The invention also provides oxazolidinone sulphonate having the formula: The invention further provides oxazolidinone benzaldehyde having the formula: CH3 N The process described in this invention is superior to the conventional processes as the process consistently produces material of high quality suitable for use as a drug substance. Specifically product purity of greater than 99.5% is achieved with no single impurity present above a threshold of 0.10%, as described in ICH guidance Q3A(R2) for impurities in new drug substances.

Brief Description of the Drawings The invention will be more clearly understood from the following description of an ‘embodiment thereof, given by way of example only, with reference to the accompanying drawings, in which: - Fig. 1 is an infra-red spectrum (kBr disc) of oxazolidinone sulphonate; - 5 _ Fig. 2 is a ‘H NMR spectrum (CDCI3, 300 MHz) of oxazolidinone benzaldehyde; Fig. 3 is a “H NMR spectrum (CDCI3, 75 MHZ) of oxazolidinone benzaldehyde; Fig. 4 is an infra-red spectrum (kBr disc) of oxazolidinone benzaldehyde; Fig. 5 is a ‘H NMR spectrum (CDCI3, 300 MHZ) of oxazolidinone benzyl alcohol; Fig. 6 is a 13H NMR spectrum (CDCI3, 75 MHZ) of oxazolidinone benzyl alcohol; and Fig. 7 is an infra-red spectrum (kBr disc) of oxazolidinone benzyl alcohol.

Detailed Description The process for preparing bisoprolol according to the invention can be summarised as follows: aagta. ‘ flaw }”3f‘ mwdmuw Oxazoiifiraone Benzyiedoohd (AP! Qarling «wanes; gs LOWY Bisofifiawcmde xam le 1 — St e 1: S thesis of Oxazolidinone Sul honate Ste 1 CH3 CH3 J\ '0 °\ MeOH k CH CH cm fl/Y\0H + 3 T 3 7)» CH3 N/Y\oH H N OH 0 30 a O O Isopropylaminopropanediol Dimethylcarbonate M.W.:133.2 M.W.:90.1 [Intermediate - not isolated] MIBK/DIW, NaOH !CHsrCH2)aI4N(Hs04) MTBE Ofij \~ 0/ S\\O M.W.:176.6 cHg\N/Y\ o o Oxazolidinone Sulphonate The following details describe the manufacture of a typical batch A reactor is charged with 392 kg of isopropylaminopropanediol, approximately 240 L of methanol, 6 to 7L of sodium methoxide (30%) and 270 L of dimethylcarbonate. The contents were heated up to allow reaction to occur.

Solvent is removed by distillation.

L Water and ca 450 L of methylisobutylketone (MIBK) are then charged to the reactor. The reactor contents are then cooled down to <25°C.

Tetrabutylamrnoniumhydrogensulphate (ca 2.5kg) and 520 kg of benzenesulphonylchloride are then added to the vessel under cooling. 30% sodium hydroxide is added to the reactor The reactor contents are heated and phase separation performed, removing the aqueous layer. Solvent is distilled and the product oxazolidone sulphonate is isolated from methyl-tert-butylether (MTBE).

Fig. 1 illustrates the infra red spectrum of oxazolidinone sulphate.

Purity HPLC >98% _ 3 - Stationary phase: octadecylsilyl silica gel for chromatography Mobile phase: a mixture of methanol water buffered with potassium hydrogen phosphate and triethylamine Oxazolidinone sulphonate is a novel intermediate and may used for the manufacture of [3-blockers such as Acebutolol, Alprenolol, Atenolol, Betaxolol, Bisoprolol, Esmolol and Metoprolol.

Exam le 2 —— S thesis of Oxazolidinone benzaldeh de Ste 2 CHO is 0\ DMF CH CH0 3 CH3 AK»/‘o’s\O + K2003 ) /K /YO CH3 N 0 0 OH 0 0 Oxazolidi none Sulphonate 4-Hydroxybenzaldehyde Oxazolidinone Benzaldehyde M.W.:299.3 M.W.: 122.1 |\,1o|_ VVL; 25329 A reaction vessel is charged with 154.5kg of 4-hydroxybenzalclehyde, 600 L of dimethylforrnamide (DMF), 100 kg of potassium carbonate and 475 kg of oxazolidinone sulphonate. The mixture is agitated and heated and held until reaction completion.

The reactor contents are then cooled down and vacuum is applied, solvent is distilled off and discarded. Water is added to the reactor to facilitate crystallisation and product isolation.

NMR spectra of oxazolidinone benzaldehyde are illustrated in Figs. 2 and 3. An infra-red spectrum for the product is illustrated in Fig. 4.

Purity HPLC 298%, 51% 4-hydroxybenzaldhyde Stationary phase: octadecylsilyl silica gel for chromatography _ 9 _ Mobile phase: a mixture of methanol water buffered with potassium hydrogen phosphate and triethylamine Exam le 3 — Alternative S nthesis of Oxazolidinone benzaldeh de Ste 2 JC:a O 0 CH3 ’ \ MeOH CH3 3/\K\oH + cm T CH3 _____> CH3 N/w/\OH OH 0 CH3ONa )_o Isopropylaminopropanediol Dimethylcarbonate O M.W.:1-33.2 M.W.:90.1 [Intermediate - not isolated] solo‘ MIBK/DIW, NaOH [CH3(CH2)al4N(H304) M.W.."l76.6 cHo cHo CH3 r («Q CH3 N/Y\0 K2603 CH3 N/YO/5&0 )—o )—o 0 on 0 0X3Z0|ldin°n6 Benzaldehyde 4-Hydroxybenzalclehyde Oxazolidinone Sulphonate Mol. Wt.: 263.29 M.W.: 122.1 [intermediate not isolated] A vessel is charged with 100 g of isopropylaminopropanediol, methanol, 3-4 g of sodium methoxide 30% and 70 ml of dimethylcarbonate. The vessel contents are heated up to allow reaction to occur. Solvent is removed by distillation. ml water and methylisobutylketone are then charged to the reaction. The reaction mixture is then cooled down to <25°C.

Tetrabutylammoniumhydrogensulphate (ca 0.5g) and 145g of benzenesulphonylchloride are then added to the reaction mixture under cooling. % sodium hydroxide is added to the reaction mixture.

The reactor contents are heated and phase separation performed, removing the aqueous layer. Solvent is distilled and the product dissolved in 380 ml dimethylforamide.

To the reaction vessel is charged 55 g of potassium carbonate and 85 g of 4- hydroxybenzaldehyde. Thepmixture is agitated, heated, and held until reaction completion.

The reactor contents are then cooled down and vacuum is applied, solvent is distilled off and discarded. Water is added to the reaction mixture to facilitate crystallisation and the product is isolated.

Purity HPLC 298%, 51% 4-hydroxybenzaldhyde Stationary phase: octadecylsilyl silica gel for chromatography Mobile phase: a mixture of methanol water buffered with potassium hydrogen phosphate and triethylamine In the specific case of bisoprolol manufacture the key oxazolidinone benzaldehyde intermediate may also be prepared in a “telescoped” process described in this example 3, this process is more efficient as the use of MTBE for the isolation of oxazolidinone sulphonate is eliminated. This results in reduced waste disposal costs and a 50% reduction in the requirement for solids separations equipment.

Example 4 — Alternative Synthesis of Oxazolidinone benzaldehyde (Step 2) CH3 CH3 J\ »° °\ MeOH J\ CH3 fl/\'/\°H + CH3 \H/ CH3 """'?>' CH3 N/w/\oH O CH3ONa ; OH 0 O Isopropylaminopropanediol Dimelhylcarbonate M-W-I133-2 M.W.:90.1 [Intermediate - not isolated] SO30] E:|/ max, E!3N M.W.:176.6 CH0 CH0 J\ \ /Y\o «T J\ \ F OH CH3 ” K2003 o Oxazolidinone Benzaldehyde Mol. Wt: 263.29 -Hydroxybenzaldehyde Oxazolidinone Sulphonate M.W.: 122.1 [intermediate not isolated] _ 11 - A vessel is charged with 100 g of isopropylaminopropanediol, methanol, 3-4 g of sodium methoxide 30% and 70 ml of dimethylcarbonate. The vessel contents are heated up to allow reaction to occur. Solvent is removed by distillation and ca 400 ml methylisobutylketone is then charged to the reaction. The reaction mixture is then cooled and 80g of triethylamine and 145g of benzenesulphonylchloride are added.

Water is added and the reaction mixture is heated and phase separation performed, removing the aqueous layer. Solvent is distilled and the product dissolved in 380 ml dimethylforarnide.

To the reaction vessel is charged 55 g of potassium carbonate and 85 g of 4- hydroxybenzaldehyde. The mixture is agitated, heated, and held until reaction completion.

The reactor contents are then cooled down and vacuum is applied, solvent is distilled off and discarded. Water is added to the reaction mixture to facilitate crystallisation and the product is isolated.

Purity HPLC 398%, _<_l% 4-hydroxybenzaldhyde Stationary phase: octadecylsilyl silica gel for chromatography Mobile phase: a mixture of methanol water buffered with potassium hydrogen phosphate and triethylamine In the specific case of bisoprolol manufacture the key oxazolidinone benzaldehyde intermediate may also be prepared in a “telescoped” process described in this example 4. This process is more efficient than the process described in examples 2 and 3, as the use of triethylamine under non aqeous reaction conditions for the coupling reaction between oxazolidinone sulphonate and benzenesulphonyl chloride is more efficient. This results from a reduction in side reactions under aqueous conditions which lead to the formation of sodium benzenesulphonate as a by-product. _ 12 - Example 5 — Step 3 — Conversion of Benzaldehyde to Benzylalcohol CHO CHZOH CH CH3 J\3 / NaBH4 n-Butanol J\ / .:_?__.:._> CH3 N/W/\o CH3 N/»/\0 o K2CO3, mw o o 0 Oxazolidinone Benzylalcohol M.W.: 265.3 Oxazolidinone Benzaldehyde M.W.: 263.3 Sodium borohydride (1 1Kg) in a mixture of water (71L) and sodium hydroxide (0.3L), to n-butanol (300L). Water (l50L) potassium carbonate and oxazolidinone benzaldehyde (271Kg) are charged to a Vessel.

The vessel contents are heated up to 100°C, cooled and ethyl acetate (IOOL) is charged to the vessel. Water or brine is used for washing and solvent is distilled off and the product is isolated from ethyl acetate.

NMR spectra of oxazolidinone benzaldehyde are illustrated in Figs. 5 and 6. An infra-red spectrum for the product is illustrated in Fig. 7.

Purity HPLC 399% Stationary phase: octadecylsilyl silica gel for chromatography Mobile phase: a mixture of methanol water buffered with potassium hydrogen phosphate and triethylamine Example 6: Purification of Bisoprolol Base Bisoprolol base is formed from the oxazolidinone benzyl alcohol by an acid catalysed coupling with isopropyl oxitol, followed by alkaline hydrolysis of the oxazolidinone ring. The resultant bisoprolol base maybe further purified either by distillation or crystallation.

Example 7: Salt Formation _ 13 - The purified bisoprolol base is converted to Pharmacopoeia grade bisoprolol fumarate by addition of fumaric acid to bisoprolol base in acetone.

Example 8: Bisoprolol Base for use as a drug substance Charge bisoprolol fixmarate (30Kg) in a mixture of water (301L) and sodium methyl-tert-butylether (105L), add aqueous sodium hydroxide to alkaline pH.

Split the lower aqeous layer to waste and wash the product layer with water.

Bisoprolol base is isolated following solvent removal by distillation.

Patches are routinely used for the controlled release of drugs via the trans dermal route, the approach is advantageous over oral administration which can result in irregular and unpredictable blood plasma levels. Bisoprolol is normally administered in oral solid dose form as the fiimarate salt, but is not suitable for controlled release from transdermal patch formulations. It has been found that Bisoprolol base prepared as described in this application is particularly suited to controlled release from transdermal patch formulations.

The invention is not limited to the embodiment hereinbefore described, with reference to the accompanying drawings, which may be varied in and detail.

Claims (5)

Claims

1. A process for preparing bisoprolol base comprising converting bisoprolol fiimarate to bisoprolol base and isolating the bisoprolol base.

2. A process for preparing bisoprolol base comprising the steps of:- reacting oxazolidinone sulphonate with 4-hydroxybenzylaldehyde to form oxazolidinone benzaldehyde; 10 forming oxazolidone benzylalcohol from oxazolidone benzaldehyde; subsequently reacting oxazolidinone benzylalcohol with isopropyl 15 oxitol to form bisoprolol base; reacting bisoprolol base with fumaric acid to form bisoprolol fumarate; and 20 converting bisoprolol fiimarate to bisoprolol base

3. A process as claimed in claim 2 comprising purifying bisoprolol base formed on reaction of oxazolidinone benzylalcohol with isopropyl oxitol. 25

4. A process as claimed in claim 3 wherein the bisoprolol base is purified by distillation.

5. A process as claimed in claim 3 wherein the bisoprolol base is purified by crystallisation.